JP2018527912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527912A5 JP2018527912A5 JP2018506135A JP2018506135A JP2018527912A5 JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5 JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 114
- 102000036639 antigens Human genes 0.000 claims description 114
- 108091007433 antigens Proteins 0.000 claims description 114
- 239000012634 fragment Substances 0.000 claims description 113
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 22
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 19
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000025171 antigen binding proteins Human genes 0.000 description 6
- 108091000831 antigen binding proteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201506227V | 2015-08-06 | ||
| SG10201506227V | 2015-08-06 | ||
| PCT/EP2016/068780 WO2017021540A1 (en) | 2015-08-06 | 2016-08-05 | Il2rbeta/common gamma chain antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527912A JP2018527912A (ja) | 2018-09-27 |
| JP2018527912A5 true JP2018527912A5 (enExample) | 2019-09-19 |
| JP6908591B2 JP6908591B2 (ja) | 2021-07-28 |
Family
ID=56889037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506135A Active JP6908591B2 (ja) | 2015-08-06 | 2016-08-05 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10472421B2 (enExample) |
| EP (2) | EP3428193B1 (enExample) |
| JP (1) | JP6908591B2 (enExample) |
| KR (1) | KR102753399B1 (enExample) |
| CN (2) | CN115925939A (enExample) |
| AU (1) | AU2016301970A1 (enExample) |
| CA (1) | CA2994906A1 (enExample) |
| CY (1) | CY1121197T1 (enExample) |
| DK (1) | DK3328894T3 (enExample) |
| ES (2) | ES2710618T3 (enExample) |
| HU (1) | HUE043421T2 (enExample) |
| PL (1) | PL3328894T3 (enExample) |
| PT (1) | PT3328894T (enExample) |
| TR (1) | TR201901445T4 (enExample) |
| TW (1) | TW201713699A (enExample) |
| WO (1) | WO2017021540A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| CN115925939A (zh) | 2015-08-06 | 2023-04-07 | 新加坡科技研究局 | IL2Rβ/通用γ链抗体 |
| HUE068936T2 (hu) | 2016-06-10 | 2025-02-28 | Gadeta B V | Új eljárás tumorellenes vagy fertõzés elleni választ közvetítõ deltaT-sejt- (vagy gammaT-sejt-) receptor-láncok vagy azok részeinek azonosítására |
| AU2018268087B2 (en) | 2017-05-18 | 2022-03-17 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| CN111954680B (zh) * | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| WO2019222547A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| BR122021012517A2 (pt) | 2018-08-06 | 2021-08-10 | Medikine, Inc. | Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante |
| KR20250160211A (ko) | 2018-08-30 | 2025-11-11 | 이뮤니티바이오, 인크. | 다중-사슬 키메라 폴리펩타이드 및 이의 용도 |
| CN113365663B (zh) | 2018-08-30 | 2025-11-21 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| WO2020047473A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| TW202031683A (zh) | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| MX2021008958A (es) | 2019-02-01 | 2021-11-04 | Regeneron Pharma | Proteínas de unión a antígeno del receptor gamma anti-il2. |
| AU2020294797B2 (en) | 2019-06-21 | 2025-12-18 | Immunitybio, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| EP4055036A4 (en) | 2019-11-05 | 2024-02-28 | Medikine, Inc. | DUAL IL-2R AND IL-7R BINDING CONNECTIONS |
| AU2020380296A1 (en) | 2019-11-05 | 2022-06-16 | Medikine Inc. | IL-2RβγC binding compounds |
| WO2021105988A1 (en) | 2019-11-26 | 2021-06-03 | Ramot At Tel-Aviv University Ltd. | Antibodies to carbohydrate antigens |
| CN114901310A (zh) * | 2019-12-24 | 2022-08-12 | 尼尔路金治疗公司 | 使用il-2受体激动剂和免疫检查点抑制剂的组合疗法 |
| AU2021217959A1 (en) | 2020-02-03 | 2022-08-18 | Medikine, Inc. | IL-7Rα binding compounds |
| JP2023514128A (ja) | 2020-02-03 | 2023-04-05 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒαγｃ結合化合物 |
| JP2023513573A (ja) | 2020-02-11 | 2023-03-31 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢性および炎症性疾患を治療する方法 |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| CN115397852B (zh) | 2020-02-16 | 2023-08-11 | 奥罗斯生物科学公司 | 工程化抗il-2抗体 |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| BR102020009679A2 (pt) * | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247604A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| US12540188B2 (en) | 2020-08-05 | 2026-02-03 | Synthekine, Inc. | IL10Rα/IL2Rγ synthetic cytokines |
| CA3190486A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10 receptor binding molecules and methods of use |
| AU2021320226A1 (en) | 2020-08-05 | 2023-03-23 | Synthekine, Inc. | gp130 binding molecules and methods of use |
| WO2022031929A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12rb1-binding molecules and methods of use |
| US20230272094A1 (en) * | 2020-08-05 | 2023-08-31 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
| EP4192502A4 (en) | 2020-08-05 | 2024-10-09 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| US12157773B2 (en) | 2020-08-05 | 2024-12-03 | Synthekine, Inc. | IL27RAlpha binding molecules and methods of use |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| US12018085B2 (en) | 2020-08-05 | 2024-06-25 | Synthekine, Inc. | Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases |
| US12077594B2 (en) | 2020-08-05 | 2024-09-03 | Synthekine, Inc. | IL2RG binding molecules and methods of use |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| WO2022032042A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12 receptor synthetic cytokines and methods of use |
| CN116322754A (zh) | 2020-08-05 | 2023-06-23 | 辛德凯因股份有限公司 | Il10ra结合分子及使用方法 |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| WO2022032005A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10rb binding molecules and methods of use |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| US20250333520A1 (en) * | 2021-01-11 | 2025-10-30 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| US12162945B2 (en) | 2021-03-05 | 2024-12-10 | Immunome, Inc. | EPHA2 antibodies |
| JP2024510291A (ja) * | 2021-03-16 | 2024-03-06 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫疾患を治療するための二機能性分子 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| CA3229748A1 (en) | 2021-08-26 | 2023-03-02 | Akifumi Kato | Bispecific antibody that binds to cd116 and cd131 |
| AU2022347445A1 (en) | 2021-09-17 | 2024-04-04 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| JP2024541048A (ja) * | 2021-11-02 | 2024-11-06 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | 抗ｃｄ１２２抗体、抗ｃｄ１３２抗体、及び関連する二重特異性結合性タンパク質 |
| EP4469163A1 (en) | 2022-01-24 | 2024-12-04 | Novimmune S.A. | Composition and methods for the selective activation of cytokine signaling pathways |
| EP4472661A2 (en) * | 2022-02-04 | 2024-12-11 | The Board of Trustees of the Leland Stanford Junior University | Surrogate cytokine polypeptides |
| EP4486368A1 (en) | 2022-03-02 | 2025-01-08 | ImmunityBio, Inc. | Method of treating pancreatic cancer |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025534413A (ja) * | 2022-09-30 | 2025-10-15 | フォルテ サブシディアリー，インク． | 抗ｃｄ１２２抗体およびその使用 |
| WO2024086754A2 (en) * | 2022-10-19 | 2024-04-25 | Tentarix Biotherapeutics, Inc. | Multi variable domain therapeutic immunoglobulin |
| EP4646225A1 (en) * | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| EP4646274A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| TW202434646A (zh) * | 2023-02-22 | 2024-09-01 | 大陸商百奧賽圖(北京)醫藥科技股份有限公司 | 抗il2ra抗體及其用途 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026033139A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2026033134A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| US20260049118A1 (en) | 2024-08-19 | 2026-02-19 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804578B1 (en) | 1995-01-09 | 2008-07-16 | Boehringer Ingelheim International GmbH | Il-2r-associated polypeptide and dna molecules coding therefor |
| AU2937597A (en) * | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US20070098685A1 (en) | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| JP2010513245A (ja) * | 2006-12-14 | 2010-04-30 | アクトジェニックス・エヌブイ | 免疫調節を誘起するための結合分子の送達 |
| EP2560994B1 (en) | 2010-04-08 | 2016-10-12 | JN Biosciences LLC | Antibodies to cd122 |
| WO2013168150A1 (en) * | 2012-05-07 | 2013-11-14 | Immune Pharmaceuticals Ltd. | Method of generating human monoclonal antibodies |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| EP2885002A4 (en) * | 2012-08-14 | 2016-04-20 | Ibc Pharmaceuticals Inc | BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20150093399A1 (en) * | 2013-08-28 | 2015-04-02 | Bioasis Technologies, Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| CN115925939A (zh) | 2015-08-06 | 2023-04-07 | 新加坡科技研究局 | IL2Rβ/通用γ链抗体 |
-
2016
- 2016-08-05 CN CN202210993771.XA patent/CN115925939A/zh active Pending
- 2016-08-05 US US15/750,425 patent/US10472421B2/en active Active
- 2016-08-05 KR KR1020187006234A patent/KR102753399B1/ko active Active
- 2016-08-05 JP JP2018506135A patent/JP6908591B2/ja active Active
- 2016-08-05 US US15/229,336 patent/US10167338B2/en active Active
- 2016-08-05 TW TW105124993A patent/TW201713699A/zh unknown
- 2016-08-05 WO PCT/EP2016/068780 patent/WO2017021540A1/en not_active Ceased
- 2016-08-05 EP EP18187373.8A patent/EP3428193B1/en active Active
- 2016-08-05 ES ES16762975T patent/ES2710618T3/es active Active
- 2016-08-05 HU HUE16762975A patent/HUE043421T2/hu unknown
- 2016-08-05 PL PL16762975T patent/PL3328894T3/pl unknown
- 2016-08-05 CN CN201680046297.2A patent/CN107922496B/zh active Active
- 2016-08-05 CA CA2994906A patent/CA2994906A1/en active Pending
- 2016-08-05 DK DK16762975.7T patent/DK3328894T3/en active
- 2016-08-05 EP EP16762975.7A patent/EP3328894B1/en active Active
- 2016-08-05 ES ES18187373T patent/ES2841799T3/es active Active
- 2016-08-05 PT PT16762975T patent/PT3328894T/pt unknown
- 2016-08-05 AU AU2016301970A patent/AU2016301970A1/en not_active Abandoned
- 2016-08-05 TR TR2019/01445T patent/TR201901445T4/tr unknown
-
2018
- 2018-02-28 US US15/908,218 patent/US10472423B2/en active Active
- 2018-03-16 US US15/922,921 patent/US10246512B2/en active Active
- 2018-08-24 US US16/112,008 patent/US10696747B2/en active Active
-
2019
- 2019-01-29 CY CY20191100118T patent/CY1121197T1/el unknown